Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026

Tango Therapeutics, Inc.

2024-Q1 EPS reported -$0.35 revenue$6,471,000

Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.
R&D expense rose to $38.1M from $28.0M due to clinical program advancement.
Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.
PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.

Period: the first quarter ended March 31, 2024
Revenue: $6.5 million
Net income: $37.9 million
EPS: $0.35 per share
Result: reported results

Exact text from the filing

held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.